Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.
Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV
Secondary outcomes
• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate participant perception of, and satisfaction with, LAI CAB/RPV for the treatment of HIV | Participants will be asked to complete a 32-item paper questionnaire relating to their HIV treatment of LAI CAB/RPV. Questions will focus on how their daily life and quality of life has been affected by switching to LAI CAB/RPV. The questionnaire that will be used is not a standardized questionnaire but rather a questionnaire that was developped by the study team. | Within the first 12 weeks of the study |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants with virologic suppression at months 5 and 11 after initiation of LAI CAB/RPV | Months 5 and 11 | |
| Proportion of participants that experience loss of virologic suppression by month 11 | Month 11 |
Not provided
Inclusion Criteria:
Not provided
Not provided
Participants will be recruited at one of the participating HIV reference centers (HRCs). These centers are part of the 12 official HIV treatment centers in Belgium and work in concert as members of the Belgian Research on AIDS & HIV Consortium (BREACH).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rakan Nasreddine, MD | Contact | +32 2 535 4130 | rakan.nasreddine@stpierre-bru.be |
| Name | Affiliation | Role |
|---|---|---|
| Stéphane De Wit, MD/PhD | Belgian Research on AIDS & HIV Consortium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Saint-Pierre University Hospital | Recruiting | Brussels | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Description of HIV resistance-associated mutations that are present at the time of loss of virologic suppression | If a participant experiences loss of virologic suppression, then if an HIV resistance test was performed at that time, the resistance-associated mutations observed will be reported. | Month 11 |
| Proportion of participants with a viral blip at months 5 and 11 | Months 5 and 11 |
| Change, from baseline, of CD4+ T-cell count and CD4+/CD8+ ratio at months 5 and 11 | Months 5 and 11 |
| Proportion of participants that are adherent to treatment at months 5 and 11 | LAI CAB/RPV must be taken every two months, which therefore requires that a target date be specified in advance of when the next treatment injection should be. This measure will evaluate the proportion of participants that presented to their clinic to receive their treatment either on the target date or within 7 days after (this will be considered adherent) and the proportion of participants that received their treatment more than 7 days after their target date (this will be considered non adherent) | Months 5 and 11 |
| Proportion of participants that discontinue their treatment over the study period | Month 11 |
| Incidence of discontinuation of treatment over the study period | This measure will be reported in person/years | Month 11 |
| Reasons for discontinuation of treatment over the study period | This measure will report all the reasons for which participants discontinued their treatment | Month 11 |
| Time to discontinuation of treatment over the study period | This measure will be reported by median time to discontinuation (months) and inter-quartile range | Month 11 |
| Proportion of participants that experience injection-site reactions (ISRs) and acceptability of ISRs | Within the first 12 weeks of the study |
| Change in weight from baseline and a ≥10% weight gain from baseline at months 5 and 11 | Months 5 and 11 |
| Proportion of participants that become hepatitis B virus (HBV) seropositive at months 5 and 11 | Months 5 and 11 |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |